An experimental drug is found to preferentially dilate autoregulatory coronary arterioles without affecting large conducting vessels. It is likely to:
Evoke coronary steal phenomenon Mitigate classical angina but not variant angina Produce tachycardia as an adverse effect Useful in CHF